eart failure is a life-threatening and costly disease. 1-3 Repeated hospitalization due to heart failure increases medical costs and is also associated with the prognosis of these patients. 4 Early identification of heart failure-associated problems and early intervention before hospitalization would relieve some of this burden. 5 Fluid retention is the most common cause of heart failure-associated hospitalization. 6, 7 The fluid retention detection algorithm (Fluid index in OptiVol, Medtronic Inc, Minneapolis, MN, USA) was designed to detect this common cause of heart failure-associated events. However, volume loss events such as low output syndrome due to dehydration as a result of excessive diuresis and gastrointestinal bleeding due to anticoagulation agents are often observed and are also severe problems.
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Thoracic impedance reflects not only fluid retention, but also fluid depletion. Actually, the feasibility of early detection of volume loss events has been shown in an animal model. 8 However, the clinical feasibility of a change in thoracic impedance to detect volume loss events associated with heart failure is not known.
The present study investigated the association between volume loss events and increased thoracic impedance in heart failure patients (New York Heart Association [NYHA] II, III and IV) with cardiac resynchronization therapy/defibrillators (CRTD) and implantable cardioverter defibrillators (ICD) with Intrathoracic Impedance Reflects Volume Loss Event continuous intrathoracic impedance monitoring.
Methods
This study retrospectively analyzed continuously monitored thoracic impedance for 18,615 days from 51 consecutive chronic heart failure patients (NYHA II, III and IV) undergoing CRTD or ICD implantation with the OptiVol Fluid Status Monitoring System (Medtronic Inc) between September 2009 and September 2011 at the University of Tokyo Hospital. Blood sampling performed once a month for the evaluation of volume loss or bleeding events was required for inclusion in this study. The most recent 1 year record of continuous thoracic impedance of each patient was analyzed. The analyzed period in- cluded the time from the pacemaker/defi brillator clinic visit until after over 1 year from device implantation in order to avoid non-specifi c thoracic impedance changes arising from infl ammatory changes, fl uid accumulation or infection around the generator. Upward deviation of thoracic impedance was defi ned as a positive deviation of thoracic impedance above the reference line (PDI). Small changes within 3 ohms for impedance change from the reference line was not counted as a PDI. Elevation impedance over 3 ohms up to 5 ohms above the reference was defi ned as a small PDI. Spike PDI was defi ned as elevation over 5 ohms over the reference line for a short time (within 4 days). A large PDI was defi ned as an elevation of the impedance over 5 ohms and continuing for at least 4 days. Three different types of PDI were defi ned by the degree of deviation and the duration of the deviated period from the reference line (Figure 1) . Volume loss events were analyzed using the following criteria: increases in blood urea nitrogen/serum creatinine ratio 2 times that observed on the prior blood test, the existence of clinical features of dehydration such as thirst, cutaneous dryness or low output syndrome that required clinical manipulation, including education regarding water intake, changing medications, rehydration therapy, blood infusions, catecholamine administration for low output syndrome and/or hospital admission.
A newly developed scale defi ned the clinical severity of the volume loss events as follows: 1 point, only education regarding water intake was required for recovery from dehydration; 2 points, adjustments to medications were required for recovery from dehydration or bleeding; 3 points, admission was required for recovery from dehydration, low output syndrome or bleeding; 4 points, catecholamine administration or blood infusion was required for recovery from dehydration, low output syndrome or bleeding.
The exclusion criteria were NYHA I patients at 1 year after device implantation, device-associated complications such as infection at the implanted site, lead troubles and the requirement of additional surgical manipulation after the fi rst implantation. Those with right side implantation and device infection, thus leading to diffi culties or hemodialysis, were also excluded from the study.
For each patient, blood tests were performed at least once a month to regularly evaluate dehydration and bleeding. If the interval between consecutive blood tests was more than 2 months, then the patient was excluded from this study.
The established protocol was in accordance with the Helsinki Declaration (2000 revision) and was approved by the institutional review board of the University of Tokyo Hospital. Written information consent was obtained from each patient before participation in the study.
Statistical Analysis
All data are expressed as the mean ± SD. The positive predictive values (PPVs) were calculated using Bayes' formula. Linear regression was used for the correlation analyses, which were expressed as Pearson correlation coeffi cients between thoracic impedance and the dehydration and bleeding event scale.
Results

Patients
There were a total of consecutive 51 chronic heart failure pa- Values are expressed as mean ± SD NYHA, New York Heart Association; QRS, QRS wiath; EF, ejection fraction; CAD, coronary artery disease; HT, hypertension; DM, diabetes mellitus; LBBB, left bundle branch block; RBBB, right bundle branch block; SSS, sick sinus syndrome; AF, atrial fibrillation; HF, heart failure; ACE, angiotensin converting enzyme. Intrathoracic Impedance Refl ects Volume Loss Event tients undergoing CRT/ICD implantation during the period of enrollment. Fifteen patients were excluded from the analysis based on the exclusion criteria (irregularity of blood sampling intervals (n=13) or hemodialysis (n=2)), thus a total of 36 adults patients (30 males, 6 females) were investigated ( Table 1) . Over 1 year passed after device implantation in all patients. The mean ± SD age was 59.6±15.0 years. The causes of chronic heart failure were: ischemic cardiomyopathy (n=11) and non-ischemic cardiomyopathy (dilated cardiomyopathy) (n=25). All patients were of NYHA functional class II to IV at the time of implantation. In addition, 52.8% of patients were of NYHA class III and 25.0% were of class IV at the time of enrollment. The standard treatments were administered for chronic heart failure including renin-angiotensin inhibitors, β-blockers, diuretics, aldosterone antagonist, and anticoagulants.
PDI Data Obtained During 1-Year Follow-up Periods
Two hundred and thirty-seven PDIs and 98 volume loss events, including 96 dehydrations and 2 bleedings, were recorded during the 1-year follow-up period, which was more than 1 year after device implantation ( Table 2 ). All PDIs were analyzed for peak level and duration (Figure 1) . This result suggests that PDIs with high peaks and long duration might refl ect dehydration or bleeding events with high PPVs. For clinical convenience, 4 categories of PDI were defi ned, including spike PDI, large PDI, small PDI and no PDI (Figure 2) . The PPVs for detecting dehydration and bleeding events were analyzed based on these criteria.
Large PDIs Refl ected Volume Loss Events With a High Positive Predictive Value
The sensitivity and PPV for a small PDI was 38.8% and 22.1%, respectively, for a spike PDI it was 31.6% and 51.7%, respectively, and for a large PDI it was 17.3% and 100%, respectively ( Table 3) . Although all PDI showed a high sensitivity, the PPV was low. In contrast, a spike PDI showed an intermediate high PPV for volume loss events. In addition, a large PDI showed a high PPV for volume loss events.
Volume Loss Case 1: Dehydration Case
Figures 3A-C summarizes a case in which a patient with dilated cardiomyopathy was hospitalized due to volume retention. A CRT (Concerto C174AWK, Medtronic Inc) had been performed for repeated acute decompensated heart failure 2 years before this hospitalization. Intensive care was administered for congestive heart failure with diuretics and infusion of atrial natriuretic peptide to improve pulmonary congestion. However, excessive use of diuretics provoked signifi cant dehydration after recovery from fl uid retention. The time-course of thoracic impedance showed a dip below the reference line, followed by a large PDI pattern. This pattern refl ected congestion and dehydration due to the over use of diuretics (Figures 3A,B) . Interestingly, a signifi cant elevation of blood urea nitrogen (BUN)/serum creatinine (Cr) ratio and significant symptoms of dehydration were observed during periods of large PDI ( Figure 3C) . Moreover, impedance increased 3 days prior to symptoms of dehydration and BUN/Cr ratio elevation. These results might indicate that the increase in the thoracic impedance prior to clinical symptoms and/or blood chemistry data might indicate dehydration. Figure 4 summarizes a case of a patient with chronic heart failure due to ischemic cardiomyopathy. He had atrial fi brillation and had taken oral anti-coagulants along with dual antiplatelet agents for drug-eluting stent implantation. Anemia from gastrointestinal bleeding due to gastric ulceration disrupted his hemodynamics. A blood transfusion was performed after the administration of saline because of low output syndrome due to rapid bleeding. A large PDI in thoracic impedance was recorded, as shown in Figures 4A and B . An acute increase of thoracic impedance from baseline and a relatively slow recovery was consistent with the rapid clinical course of volume loss and its recovery. In fact, the hemoglobin level was decreased from 110 g/L to 79 g/L and recovered to baseline after a blood transfusion ( Figure 4B) . These results indicated that a large PDI was consistent with the period of volume loss events due to bleeding.
Peak Level and Duration of PDI Correlated With the Severity of Volume Loss Events
Among 86 PDIs with volume loss events, the correlation between the clinical severity of the volume loss event and the morphology of the PDI was analyzed. Dehydration and bleeding scale scores refl ecting the clinical severity of the volume loss events were defi ned based on the type of treatment provided, such education, adjustment of medications, admission, catecholamine administration for low output and blood infusions for recovery. The peak levels and durations of PDI were found to be correlated with the clinical severity of the volume loss event (Figures 5A,B) . These results indicate that the height of the PDI might predict the severity and clinical course of the volume loss event.
Discussion
Pulmonary congestion including vascular congestion and interstitial congestion would decrease intrathoracic impedance. 9, 10 The continuous monitoring of intrathoracic impedance has been used in the detection of acute decompensated heart failure. 11 OptiVol fl uid status monitoring is the application of intrathoracic impedance for the measurement of pulmonary fl uid retention. 11 In contrast, thoracic impedance is considered to increase along with fl uid loss during optimal heart failure treatment using intense diuretics. 10 Moreover, the feasibility of the concept of detecting volume loss as an increase in thoracic impedance was illustrated in an animal model. 8 However, the clinical feasibility of increased intrathoracic impedance detection of volume loss events is not known. This study defi ned several categories of positive deviation of intrathoracic impedance from the reference line (PDI) including no PDI, small PDI, spike PDI and large PDI (Figures 1A-D) . In addition, the association between these PDIs and clinical volume loss events like dehydration and bleeding were investigated in chronic heart failure patients (NYHA II, III or IV; Table 1) . A large PDI showed a high PPV (100%) for the detection of volume loss events, but this was not the case for a small PDI (22.1%) and a spike PDI (51.7%). A clinical trial investigating whether intrathoracic impedance monitoring (OptiVol) with audible patient alerts could improve the outcome of heart failure patients failed to show its clinical utility. 12 In addition, the number of hospitalizations significantly increased in the OptiVol patient alert guiding therapy group in comparison to the conventional groups. 12 The concept of identifying a decrease in thoracic impedance for the early detection of decompensated heart failure before hospitalization had been reported by many groups. 10,13-18 However, the PPV of the OptiVol patient alert is 38.1% at the nominal Fluid Index threshold. 18 It is impossible to disregard the pseudo-positive signal from a patient alert. The main cause of unnecessary hospitalization in the OptiVol patient alert group might be due to the low PPV of the Fluid index. 12 Therefore, the current study defi ned several PDI categories and analyzed which PDI showed a high PPV for the early detection of volume loss events. Although the sensitivity of a large PDI (32.1%) is by no means satisfactory, the high PPV is thought to be the most attractive indicator for the early detection of an impending volume loss event before hospitalization and for decreasing unnecessary hospitalization due to alerts from impedance monitoring.
The variability of thoracic impedance during decompensated congestive heart failure treatment followed by dehydration due to an over-dose use of diuretics showed a large PDI after a dip in the impedance under the reference line in some cases like case 1 (Figure 3) . In contrast, dehydration without prior decompensated heart failure or bleeding events showed an acute up slope from the reference line without any decrease in impedance before a large PDI, as in case 2 (Figure 4) . These different patterns around a large PDI formation might help to identify the clinical features before hospitalization.
Moreover, a correlation between the peak level of PDI and the severity of the volume loss event was observed ( Figure 5A) . Awareness of this relationship might therefore be useful when choosing a suitable strategy for treating each volume loss event.
In this study, we selected heart failure patients (NYHA II, III or IV) and excluded patients who had implanted devices within 1 year to completely avoid the impact of postsurgical edema and infl ammation in the pocket area. 11 Although, the number of enrolled patients was low, it was possible to record suffi cient volume loss events and PDIs without any surgical or infectious noise.
Study Limitations
The limitations of this study include that it was a single-center retrospective study with no of long-term follow up. Larger and prospective studies are needed to further assess the clinical feasibility of continuous intrathoracic impedance monitoring to predict volume loss events in chronic heart failure patients.
Conclusions
The present study is the fi rst demonstration of the association of continuous intrathoracic impedance monitoring by implanted devices (CRTD and ICD) and volume loss events in chronic heart failure patients. A large PDI was useful and new criteria to catch the volume loss events with high PPV in severe chronic heart failure patients after they are implanted with devices with continuous thoracic impedance monitoring was established. Continuous intrathoracic impedance monitoring might be used for the prediction of volume loss events with high PPV by using well-defi ned criteria.
